Portland initiates registration in China

Portland Orthopaedics (ASX:PLD) has initiated registration of its complete range of orthopaedic products with the State Drug Administration of China (SFDA), in a process expected to take 12 months.

Portland has begun to identify and appoint specialist Chinese local distributors, and has commissioned a consulting firm with a proven track record in the area of orthopaedic products in China to assist in this process.

When the registration process with the Chinese SFDA is complete, Portland will be allowed to promote and distribute its product ranges in China.

Portland has regulatory approval to sell a range of primary, revision and tumour hip replacement products in Australia, New Zealand, the US, Israel and Europe. The company said entry into the Asian market would be a significant milestone. Portland produces a DTC Asian series hip replacement prosthesis which is suited to the typically narrower femur of the Asian anatomy.